(NASDAQ: INAB) In8bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 68.43%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.61%.
In8bio's earnings in 2026 is -$20,658,000.On average, 5 Wall Street analysts forecast INAB's earnings for 2026 to be -$9,895,362, with the lowest INAB earnings forecast at -$13,216,371, and the highest INAB earnings forecast at -$6,617,917. On average, 6 Wall Street analysts forecast INAB's earnings for 2027 to be -$11,664,311, with the lowest INAB earnings forecast at -$16,350,149, and the highest INAB earnings forecast at -$4,330,843.
In 2028, INAB is forecast to generate $12,920,696 in earnings, with the lowest earnings forecast at -$10,082,592 and the highest earnings forecast at $55,473,720.